Its versatile handling is designed to satisfy the need for a flowable allograft product with cohesive properties, making it an attractive option for minimally invasive surgery (MIS), expandable cages and 3D-printed cages.
The biphasic mineral in SIGNAFUSE is composed of 60% hydroxyapatite and 40% beta- tricalcium phosphate; a ratio supported by multiple prospective2 and randomized controlled trials.3-5
EXOGEN uses process and promote fracture healing. It has an 86% heal rate for fractures not healing on their own1 and provides 38% faster healing of indicated fresh fractures.
National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System
EXOGEN uses natural bone healing process and promote fracture healing. It also has an 86% heal rate for fractures not healing on their own and provides 38% faster healing of fresh fractures.
Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics
“Development of new orthobiologics offerings for osteoarthritis is a core focus for Bioventus and we are pleased to begin collaborating with MTF Biologics on a solution for knee OA that will offer symptom relief and potentially delay progression of the disease,” said Tony Bihl, CEO, Bioventus.
3/27/19: OSTEOAMP SELECT Fibers, an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.
Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers, LLC
Bioventus has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers, LLC (VB), a private equity investment firm focused on developing innovative...
2/26/18: Bioventus, a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, to co-develop a next generation bone allograft solution for use in spine and trauma surgery. Terms of the agreement were not disclosed
12Page 1 of 2